Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Small Cell Lung Carcinoma 1Radiation Pneumonitis 1Pleural Effusion, Malignant 1Neoplasm, Residual 1NSCLC 1Lymphoma, Extranodal NK-T-Cell 1Lung Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

Cisplatin 8Carboplatin 8Bevacizumab 8Pleurodesis 7Talc 6Paclitaxel 6Docetaxel 5Povidone-Iodine 4Doxycycline 4Taxes 3Gemcitabine 3Drug Therapy 3Chest Tubes 3aldesleukin 2Zoledronic Acid 2Trastuzumab 2Thoracoscopy 2Sodium Chloride 2Silver Nitrate 2Pharmaceutical Preparations 2Nivolumab 2Interleukin-2 2Fluorodeoxyglucose F18 2Fentanyl 2Erlotinib Hydrochloride 2Cetuximab 2Bortezomib 2viscum album peptide 1tocilizumab 1tipifarnib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Pleural Effusion, Malignant × sugemalimab × Clear all
NCT06097962 2026-05-20

Safety and Efficacy of NK510 to Treat NSCLC

Base Therapeutics (Shanghai) Co., Ltd.

Phase EARLY_PHASE1 Recruiting
12 enrolled
Thoracic

Pleural Effusion, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡